KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Work In Process (2018 - 2025)

Acadia Pharmaceuticals has reported Work In Process over the past 8 years, most recently at $76.7 million for Q4 2025.

  • Quarterly results put Work In Process at $76.7 million for Q4 2025, up 9.98% from a year ago — trailing twelve months through Dec 2025 was $76.7 million (up 9.98% YoY), and the annual figure for FY2025 was $76.7 million, up 9.98%.
  • Work In Process for Q4 2025 was $76.7 million at Acadia Pharmaceuticals, roughly flat from $76.9 million in the prior quarter.
  • Over the last five years, Work In Process for ACAD hit a ceiling of $84.4 million in Q2 2025 and a floor of $4.6 million in Q3 2023.
  • Median Work In Process over the past 5 years was $6.7 million (2021), compared with a mean of $25.2 million.
  • Biggest five-year swings in Work In Process: dropped 27.24% in 2022 and later surged 1406.94% in 2024.
  • Acadia Pharmaceuticals' Work In Process stood at $6.8 million in 2021, then fell by 27.24% to $4.9 million in 2022, then decreased by 6.01% to $4.6 million in 2023, then surged by 1406.94% to $69.7 million in 2024, then rose by 9.98% to $76.7 million in 2025.
  • The last three reported values for Work In Process were $76.7 million (Q4 2025), $76.9 million (Q3 2025), and $84.4 million (Q2 2025) per Business Quant data.